DEVELOPMENT AND ESTIMATION OF HUMAN DOSIMETRY OF A NEW 47SC-RISEDRONATE FOR RADIOPHARMACEUTICAL APPLICATION.

Bisphosphonate risedronate (2-(3-pyridinyl)-1-hydroxyethane diphosphonic acid) was radiolabeled with scandium-47 (47Sc) as potential therapeutic radiopharmaceutical for skeletal metastases. Its time-dependent biodistribution in mice was measured and its human dosimetry was derived. The labelling process was performed at 95 °C for 30 min.

The Preparation, Biodistribution, and Dosimetry of Encapsulated Radio-Scandium in a Dendrimer for Radio-nano-pharmaceutical Application.

This study aimed to investigate the synthesis, characterization, and biodistribution of scandium nanoparticles encapsulated within poly (amidoamine) (PAMAM) dendrimers, as well as to estimate the human absorbed dose. It also aimed to examine, in particular, the amine-terminated PAMAM dendrimers in generation 5. Irradiation of the compound in the nuclear reactor resulted in the formation of Sc-radioactive complex nanoparticles.

The preparation, biodistribution, and human's absorbed dose evaluation of Radio-Scandium-HYNIC-TOC for somatostatin-receptor-positive neuroendocrine tumors therapy by animal study.

Background: Most of the neuroendocrine tumors (NETs) express Somatostatin receptors (SSTr), which are the main bases for the development of several radiopharmaceuticals for therapy and imaging of these types of tumors. In this study, 46 Scandium nuclide was used to label a peptide compound via hydrazinonicotinyl-Tyr3-Octreotide (HYNIC-TOC) and researched further for somatostatin-receptor NETs treatment.

Methods And Materials: The labeling procedure was conducted at 95°C for 10 min.

Dosimetry of Ytterbium-poly (amidoamine) Therapy for Humans' Organs.

Purpose: This investigation focuses on biodistribution of irradiated dendrimer encapsulated ytterbium-175 (Yb) and to estimate the absorbed dose from intravenous injection of PAMAM encapsulated Yb to human organs.

Methods: A dendrimer compound containing an average of 55 Yb ions per dendrimer was prepared and irradiated with neutrons for 2h at 3×10 n.cm-s- neutron flux.

Development of bone seeker radiopharmaceuticals by Scandium-47 and estimation of human absorbed dose.

In this study labeling EDTMP (ethylenediamine tetra(methylene phosphonic acid)) and HEDP (Hydroxyethylidene-1, 1-Diphosphonic Acid) as the carrier ligands with Scandium-47 were investigated. The biokinetics of the bone seeking of labeled ligands with Scandium-47 were assessed by measuring the skeletal absorbed dose and then the mice data extrapolated to human absorbed dose and compared with the Rhenium-HEDP, Samarium-EDTMP dosimetry data estimated by other researchers. Because the availability of Sc was limited we performed some preliminary studies using Sc.

Development of Dendrimer Encapsulated Radio-Ytterbium and Biodistributionin Tumor Bearing Mice.

The aim of this study is preparation of dendrimer encapsulated ytterbium-175 radio-nanoparticles and investigation of the compound chemical characteristic before and after the neutron irradiation and also study the in vivo biodistribution for targeted radiopharmaceutical dose delivery to solid tumors. For preparation of dendrimer-metal nanocomposite, a dendrimer compound containing an average of 55 Yb ions per dendrimer was prepared. The synthesized encapsulated ytterbium irradiated by neutron for 2 h at 3×10 n.

Production and purification of Scandium-47: A potential radioisotope for cancer theranostics.

In this study, production of Sc radionuclide by irradiating the natural titanium dioxide powder (TiO) in the fast neutron flux (~3*10ncms) for 4 days in Tehran Research Reactor (TRR, Iran) and separation from titanium target was investigated. The study showed the feasibility of production Sc by TRR. The separation efficiency and radiochemical purity (ScCl) of radio-scandium, Sc radionuclide purity were obtained 98%, 99% and 88% respectively.

Production, biodistribution, and dosimetry of (47)Sc-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid as a bone-seeking radiopharmaceutical.

In this study 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid (DOTMP) was used as the polyaminophosphonic acid carrier ligand and the therapeutic potential of the bone seeking radiopharmaceutical (47)Sc-DOTMP was assessed by measuring its dosage-dependent skeletal uptake and then the absorbed radiation dose of human organs was estimated. Because of limited availability of (47)Sc we performed some preliminary studies using (46)Sc. (46)Sc was produced with a specific activity of 116.